*Organization & Developments: VeraStem (2011-2018)

Parents

2011: Verastem, the 15-Month Old Christoph Westphal Venture in Cancer Stem Cells, Seeks IPO (2011)
2017: Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma
2017: Verastem Announces Pricing of Public Offering of Common Stock
2017: Verastem Beats The Odds - Verastem (NASDAQ:VSTM)
2017: Verastem: Revisiting This Small Biotech Name After ASH - Verastem, Inc. (NASDAQ:VSTM)
2017: Verastem: Too Cheap_seekingalpha.com
2018: Are Things Finally Looking Up For Verastem? - Verastem, Inc. (NASDAQ:VSTM)
2018: Post FDA Approval Take On Verastem_seekingalpha.com
2018: Reader Inquiry: Does Verastem Have Further Upside Ahead?_seekingalpha.com
2018: Verastem In CLL: Opportunity And Caution - Verastem, Inc. (NASDAQ:VSTM)
2018: Verastem Is Now A Major Freshly Derisked Small Cap Oncology Opportunity - Verastem, Inc. (NASDAQ:VSTM)
2018: Verastem_FDA Accepts New Drug Application for Duvelisib and Grants Priority Review
2018: VeraStem_Targeting A Big Return On This Small Cap Biotech_seekingalpha.com
2018: Verastem: Undervalued And Derisked_seekingalpha.com
2018: Verastem: Updates To Thesis - Verastem, Inc. (NASDAQ:VSTM)
2018: Verastem's Duvelisib And The Competition: A Comparison_seekingalpha.com
2018: We Continue To Like Verastem - Verastem, Inc. (NASDAQ:VSTM)